Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Geologica Closes Financing And Property Acquisition (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Calithera Biosciences Inc CALA

Healthcare Biotechnology
Calithera Biosciences, Inc. is a shell company. The Company is winding up its operations. The Company is seeking to sell all of its clinical assets and programs. The Company has not generated any revenue.

Recent & Breaking News (GREY:CALA)

Calithera Biosciences to Report Third Quarter 2016 Financial Results on Wednesday, November 9, 2016

GlobeNewswire November 2, 2016

15 Biggest Mid-Day Losers For Tuesday

Benzinga.com  October 25, 2016

Stocks Hitting 52-Week Lows

Benzinga.com  October 25, 2016

18 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  October 25, 2016

Calithera Biosciences to Present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology Roundtable

GlobeNewswire September 22, 2016

Calithera Announces First Patient Dosed in a Phase I Study of CB-1158, the First-in-Class Inhibitor of the Immuno-Oncology Target Arginase

GlobeNewswire September 15, 2016

Lightstone Ventures Adds Susan Molineaux as Scientific Advisor

Marketwired September 7, 2016

Calithera Biosciences Announces CB-839 Clinical Data Selected for Oral Presentation at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

GlobeNewswire September 7, 2016

Calithera Biosciences to Present at Two Healthcare Conferences in September

GlobeNewswire August 31, 2016

Calithera Biosciences Appoints Suzy Jones to Board of Directors

GlobeNewswire August 10, 2016

Calithera Biosciences Reports Second Quarter 2016 Financial Results and Recent Highlights

GlobeNewswire August 9, 2016

Calithera Announces Enrollment of First Patient in CB-839 in Combination with Checkpoint Modulator

GlobeNewswire August 4, 2016

Calithera Biosciences to Report Second Quarter 2016 Financial Results on Tuesday, August 9, 2016

GlobeNewswire August 2, 2016

Calithera Biosciences Announces FDA Acceptance of Investigational New Drug Application for CB-1158, a Novel Arginase Inhibitor Targeting an Immune Metabolic Checkpoint

GlobeNewswire July 25, 2016

Calithera Biosciences Reports CB-839 Phase I Solid Tumor Combination Data at the American Society of Clinical Oncology Annual Meeting

GlobeNewswire June 6, 2016